Path 433@2x

"We have risen to our Kingdom's call and do not take lightly our responsibility towards the health and safety of our fellow citizens"

Welcome to Avalon Pharma!

When I joined Avalon Pharma 20 years ago, the company was a Saudi Arabian SME with a clear ambition of enhancing the health and wellbeing of the people of Saudi Arabia. The growth and new milestones the company has achieved since that time are a credit to the passion and commitment of each member of our growing family. 

​​We are ambitious, competitive, innovative, dynamic and agile. Our focus is on serving the needs of the medical, pharmaceutical and scientific communities who prescribe, endorse and dispense our products. We create win-win relationships with our commercial partners, (in both the private and public sectors) and we are committed to building long-term partnerships with likeminded healthcare companies in Saudi Arabia and around the world.​

Our vision is clear and our commitment to achieving it is second to none. By understanding the needs of our customers and aligning those aspirations to our offering; we will emerge as the Kingdom of Saudi Arabia’s preferred health and beauty company. At the core of this intent is a rigorous quality assurance policy and corporate governance framework. 

In 2020 we have risen to the challenges of the uncontrollable and unfortunate circumstances that surround us. COVID-19 has changed many things in our day-to-day operation, but at the same time has illustrated our commitment to the Kingdom of Saudi Arabia, its Government and its people. We have stepped up to our Kingdom’s call and are delivering a variety of sanitisation products that help keep our people safe. We are responsible and do not take that responsibility lightly.

 While the pandemic has unfortunately brought many industries to a complete standstill, AvalonPharma is hard at work! In addition to our efforts in sanitisation products, we have also launched ezCARE (a comprehensive range of day-to-day skincare products), AvalonActiv (an uplift of the Kingdom’s trusted temporary relief of muscle and joint pain: Avalon Muscle Pain Relief Cream) and we have launched AvalonCare in 2021. In addition to many other pharmaceutical preparations that will be launched soon.

Avalon Pharma’s strategic plan is aligned with Vision2030 and the National Transformation Program 2020. We plan to make significant investments in local manufacturing, development, technology transfer, logistics, talent development and in the manufacturing of medicines and health and beauty products.

We are intent on expanding our reach; focusing on new export markets and thus allowing Avalon Pharma to emerge from its humble beginnings to a pioneering regional pharmaceuticals company.

Thank you for your interest and continued support. 

Best regards,​

Mohamed Maher Al Ghannam
Managing Director & CEO